Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
Includes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis on the management of SE
Presentation details are as follows:
Podium Presentation Details:
Thursday, October 17, 2024, 9:35-9:55 a.m. PT
- Title: Efficacy and Safety of Intravenous Ganaxolone for Treatment of Refractory Status Epilepticus: Results from the Phase 3, Double-Blind, Randomized, Placebo-Controlled RAISE Trial
-
Presenting Author: Brandon Foreman, M.D., M.S., FACNS, FNCS, Associate Professor of Neurology & Rehabilitation Medicine and Neurosurgery at the University of
Cincinnati and Associate Director for Neurocritical Care Research - Session: Late-Breaking Science Oral Platform
Poster Presentation Details:
Wednesday, October 16, 2024, 2:45-3:45 p.m. PT
- Title: High Rate of Interhospital Transfers in Status Epilepticus: Challenges in Management of Care
- Presenting Author: Henrikas Vaitkevicius, M.D., VP, Clinical Development, Marinus Pharmaceuticals
- Session: Poster Session Day 2
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009774652/en/
Investors
Sonya Weigle
Chief People and Investor Relations Officer
Marinus Pharmaceuticals, Inc.
sweigle@marinuspharma.com
Media
Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Source: Marinus Pharmaceuticals
